Rifaximin + ORT for Diarrhea

This trial examines how rifaximin, an antibiotic, combined with oral rehydration therapy (ORT), affects children with sudden diarrhea. Researchers aim to determine if adding rifaximin speeds up recovery and ensures safety for children aged 6 to 11. Children who have experienced at least three loose stools in the past day, possibly due to bacteria, and have been sick for less than 96 hours, may qualify. Participants will receive either rifaximin plus ORT or just ORT, and they must visit the clinic and provide samples to monitor their recovery. As a Phase 4 trial, this study involves an FDA-approved treatment and seeks to understand its benefits for more patients.

The trial requires participants to stop taking certain medications, such as oral antimicrobial drugs within 14 days before starting the trial and any P-glycoprotein inhibitors. If you are taking warfarin, you cannot participate in the trial.

Research has shown that rifaximin is generally safe to use. It is mainly prescribed for conditions causing diarrhea, such as traveler's diarrhea and irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is a unique antibiotic that primarily remains in the gut, minimizing side effects in other parts of the body.

In studies with adults, rifaximin was well-tolerated, with side effects similar to those of a placebo. Common side effects are mild and may include headache or nausea. The FDA has approved rifaximin for treating traveler's diarrhea, further supporting its safety.

Researchers are excited about using Rifaximin combined with oral rehydration therapy (ORT) for treating diarrhea because it brings a unique approach to managing the condition. While standard treatments typically focus on rehydration alone, Rifaximin acts as an antibiotic targeting the bacteria responsible for the diarrhea, potentially leading to quicker recovery. This combination aims to not only rehydrate patients but also address the underlying cause of the symptoms, offering a dual-action approach that could enhance overall treatment effectiveness. Unlike traditional antibiotics, Rifaximin is minimally absorbed into the bloodstream, reducing the risk of systemic side effects.

Research has shown that rifaximin can shorten the duration of acute diarrhea. In non-travel-related cases, taking rifaximin for a short period significantly reduced the duration of diarrhea. It has also proven effective for treating bacterial intestinal infections with few side effects. For individuals with irritable bowel syndrome who experience diarrhea, rifaximin improved both stomach pain and diarrhea symptoms. In this trial, one group of participants will receive rifaximin with oral rehydration therapy (ORT), while another group will receive ORT alone. This setup suggests that combining rifaximin with ORT may resolve diarrhea faster than rehydration therapy alone.¹⁴⁶⁷⁸